| Aurobindo
Pharma Ltd. has reported excellent results for the
quarter ended 30th Sep 2003.
The Total Income for the second quarter stood
at Rs.3537.8 million. (Rs.3083.2 million), an increase
of 15% over the corresponding period in the previous
year.
The
Profit before Tax for the second quarter stood at
Rs.436.1 million. (Rs.291.3 million.), an increase of
50% and the Profit after tax for the second
quarter stood at Rs.321.5 million. (Rs.205.2 million.),
an increase of 57% over the corresponding quarter in the
previous year. The
Gross profit (PBDIT) improved to 17.75% from 14%.
The net profit (PAT) improved to 9.21% from
6.73%.
The
net profit of Rs.321.5 million. is after writing off
increased R&D expenditure of Rs.58.7 million.
(Rs.28.6 million.) and a one-time asset write off of
Rs.36.2 million. relating to restructuring of
manufacturing facilities. The benefits of Vizag
facility and the manufacturing restructuring have
begun and the same can be seen in the profitability
improvement.
The
total income for the first half stood at Rs.6652.9
million. (Rs.5587.4 million.), registering a growth of
19%. The profit before tax and the profit after tax for
the first half stood at Rs.755.6 million (Rs.493.3
million.) and Rs. 552 million. (Rs.356.2 million.)
registering a sharp increase of 53%, and 55%
respectively over the corresponding period in the
previous year.
R&D
efforts: In
this quarter the company has filed 6 more patents taking
the total patents to 26.
The company has filed 13
DMFs /
COS in US /
EU markets. The
company expects to continue and augment the filings of
DMFs/COS/ANDAs in the subsequent quarters.
The company employs over 260 Scientists dedicated
to global generics business and has filed crucial non
infringing process patents successfully.
The modern bio equivalence center at Hyderabad,
with over 60 beds for conducting bio equivalence studies
of formulations, has commenced its operations. The
proposed additional R&D center at Mumbai is getting
commissioned shortly.
|
PRESS
ROOM 
